An observational study in Nonfatal Stroke, Nonfatal Myocardial Infarction and Cardiovascular Death, sponsored by The University of Hong Kong. Active, not recruiting at 1 site in Hong Kong. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-11-09.
Sponsored by The University of Hong Kong · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Stroke by The University of Hong Kong — 4 open to participants now, 5 under way, none of them phase 3. Stroke · The University of Hong Kong.
Among the 18 studies in Stroke by The University of Hong Kong, this one is the only one that started in 2020, is one of 3 observational ones, and was the 18th registered.
8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.
Browse Stroke studies →4 of the 18 studies in Stroke by The University of Hong Kong are open now, in 2 countries. Recruiting first, the newest first:
The University of Hong Kong · Sites in Hong Kong
Ages 18+
The University of Hong Kong · Sites in Hong Kong
Ages 18+
The University of Hong Kong · Sites in Hong Kong
Ages 50+
The University of Hong Kong · Sites in China
Ages 18–100 · Healthy volunteers
By country, each count listing its studies:
Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 1 started in 2020.
This study's planned enrollment of 22,000 is above the median of 150 across 1,971 observational studies indexed under Stroke.
Median enrollment 102 across the 15 interventional studies, 650 across the 3 observational. Of the 10 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
The University of Hong Kong is the lead sponsor of 1,295 studies on the registry; 351 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
1 of the studies in Stroke by The University of Hong Kong that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05300997The University of Hong KongTranslational Immunodiagnostics in Stroke (TrImS) | 2027-08-31 |
Add it to your calendar (.ics) → With an account.
Among the 18 studies in Stroke by The University of Hong Kong, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study aims at determining if the presence of adverse plaque features identified from the CT angiogram can help determine prognosis and guide treatment options.
28000
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Diagnostic Test: CTCA
Patient who is ≥ 18 years old presented with chest pain and has undergone CTA between 01-Jan-2012 and 31-Dec-2022 before treatment \- If multiple CTAs are taken, the most updated one before treatment commencement will be chosen.
Nonfatal stroke, nonfatal myocardial infarction, and cardiovascular death and all-cause death
Time frame: 5 years after CTCA examinations
Total plaque (mm³) to predict cardiac events
Time frame: 5 years after CTCA examinations
Calcified plaque (mm³) to predict cardiac events
Time frame: 5 years after CTCA examinations
Non-calcified plaque (mm³) to predict cardiac events
Time frame: 5 years after CTCA examinations
CT-FFR to predict cardiac events
Time frame: 5 years after CTCA examinations
Started Jan 2020 (actual). Primary completion is estimated for Dec 2027, 95 months after the start.
Primary completion moved once since we started tracking on Sep 25, 2026: Jun 2026 → Dec 2027, on Nov 9, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.